Minimizing Resistance Consequences After Virologic Failure on Initial Combination Therapy-Reference-Cited by-同舟云学术

Minimizing Resistance Consequences After Virologic Failure on Initial Combination Therapy

Published:2006-03 Issue:3 Volume:41 Page:323-331
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Bartlett John A.,Buda Jeffrey J.,von Scheele Birgitta,Mauskopf Josephine A.,Davis E. Anne,Elston Robert,King Martin S.,Lanier E. Randall

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference26 articles.

1. European guidelines for the clinical management and treatment of HIV-infected adults in Europe.;AIDS,2003

2. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults.;Bartlett;AIDS,2001

3. Assessing resistance costs of antiretroviral therapies via measures of future drug options.;Jiang;J Infect Dis,2003

4. Drug resistance mutations in HIV-1.;Johnson;Top HIV Med,2003

5. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).;Podzamczer;Antivir Ther,2002

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of HIV-1 subtypes and drug resistance mutations in Henan Province, China (2017–2019);Archives of Virology;2020-04-11

2. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe;BMC Infectious Diseases;2014-07-21

3. Immuno-haematologic and virologic responses and predictors of virologic failure in HIV-1 infected adults on first-line antiretroviral therapy in Cameroon;Infectious Diseases of Poverty;2014-01

4. Monitoring HIV Viral Load in Resource Limited Settings: Still a Matter of Debate?;PLoS ONE;2012-12-06

5. Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens;PLoS ONE;2012-11-26